Loading…

Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19

The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiot...

Full description

Saved in:
Bibliographic Details
Published in:The Kaohsiung journal of medical sciences 2020-06, Vol.36 (6), p.389-392
Main Authors: Tseng, Yu‐Hsin, Yang, Rei‐Cheng, Lu, Tzong‐Shi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3
cites cdi_FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3
container_end_page 392
container_issue 6
container_start_page 389
container_title The Kaohsiung journal of medical sciences
container_volume 36
creator Tseng, Yu‐Hsin
Yang, Rei‐Cheng
Lu, Tzong‐Shi
description The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiotensin system (RAS) imbalance and promotion of multi‐organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1‐7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS‐CoV‐2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1‐7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID‐19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID‐19 infection inactivating the ACE2/Ang (1‐7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID‐19 who have comorbidities and may serve as a therapeutic target for COVID‐19 treatment.
doi_str_mv 10.1002/kjm2.12237
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d6f1583bd3f24cb08845e10fdc21f841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A721986744</galeid><doaj_id>oai_doaj_org_article_d6f1583bd3f24cb08845e10fdc21f841</doaj_id><sourcerecordid>A721986744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3</originalsourceid><addsrcrecordid>eNp9ksFuEzEQQFcIRNPChQ9AlrggpATba6-9F6QqUAgU9UBB3Cyvd5w43bVTe9MqNz6Bb-RLcJpSCELIki2N37zRjKYonhA8IRjTlxfLnk4IpaW4V4woI3gsK47vFyNSYTHmnHw9KA5TWmLMqroWD4uDkrKa0pqOik_n1wEt3JDQENCwABTBO__j23ft5y4M4JPzKG3SAD3q9QatunxpdAEbFEMHaPsLVxABTc--zF7nRFI_Kh5Y3SV4fPseFZ9P3pxP341Pz97OpsenY8MlEWPRUsMZpoxrLRpRWiwwEIulNpSYUoiGCy2YrUFgrrnGQEXZmLptGitsbcujYrbztkEv1Sq6XseNCtqpm0CIc6Xj4EwHqq0s4bJs2tJSZhosJeNAsG1zKSsZya5XO9dq3fTQGvBD1N2edP_Hu4WahyslSoyF2Aqe3wpiuFxDGlTvkoGu0x7COinKcF2xqmQyo8_-QpdhHX0eVaYyJzGX_Dc117kB523Idc1Wqo4FJbWsBGOZmvyDyqeF3pngwboc30t4sUswMaQUwd71SLDarpParpO6WacMP_1zKnfor_3JANkB17nM5j8q9eH9R7qT_gQnMNPJ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424080585</pqid></control><display><type>article</type><title>Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Wiley_OA刊</source><source>Coronavirus Research Database</source><creator>Tseng, Yu‐Hsin ; Yang, Rei‐Cheng ; Lu, Tzong‐Shi</creator><creatorcontrib>Tseng, Yu‐Hsin ; Yang, Rei‐Cheng ; Lu, Tzong‐Shi</creatorcontrib><description>The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiotensin system (RAS) imbalance and promotion of multi‐organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1‐7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS‐CoV‐2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1‐7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID‐19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID‐19 infection inactivating the ACE2/Ang (1‐7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID‐19 who have comorbidities and may serve as a therapeutic target for COVID‐19 treatment.</description><identifier>ISSN: 1607-551X</identifier><identifier>EISSN: 2410-8650</identifier><identifier>DOI: 10.1002/kjm2.12237</identifier><identifier>PMID: 32492292</identifier><language>eng</language><publisher>BP, Asia: Wiley Publishing Asia Pty Ltd</publisher><subject>Angiotensin converting enzyme ; Angiotensin II - physiology ; Angiotensin Receptor Antagonists - therapeutic use ; Angiotensin-Converting Enzyme 2 ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Betacoronavirus - pathogenicity ; Betacoronavirus - physiology ; Blood pressure ; Cancer ; Cardiovascular disease ; Cells ; Comorbidity ; Conflicts of interest ; coronavirus disease 2019 ; Coronavirus Infections - drug therapy ; Coronavirus Infections - epidemiology ; Coronavirus Infections - physiopathology ; Coronaviruses ; COVID-19 ; Diabetes ; Health aspects ; Humans ; Hypertension ; Infections ; Inflammation ; Inflammatory diseases ; Kinases ; Medical prognosis ; Models, Biological ; Mortality ; Multiple organ dysfunction syndrome ; Obesity ; Pandemics ; Peptidyl-Dipeptidase A - physiology ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - physiopathology ; Proteins ; Receptor, Angiotensin, Type 1 - physiology ; Renin-Angiotensin System - drug effects ; Renin-Angiotensin System - physiology ; renin‐angiotensin system ; Review ; SARS-CoV-2 ; Severe acute respiratory syndrome ; Signal transduction ; Spike Glycoprotein, Coronavirus - physiology ; two hits</subject><ispartof>The Kaohsiung journal of medical sciences, 2020-06, Vol.36 (6), p.389-392</ispartof><rights>2020 The Authors. published by John Wiley &amp; Sons Australia on behalf of Kaohsiung Medical University.</rights><rights>2020 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley &amp; Sons Australia on behalf of Kaohsiung Medical University.</rights><rights>COPYRIGHT 2020 John Wiley &amp; Sons, Inc.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3</citedby><cites>FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2424080585?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2424080585?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,11562,25753,27924,27925,37012,37013,38516,43895,44590,46052,46476,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32492292$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tseng, Yu‐Hsin</creatorcontrib><creatorcontrib>Yang, Rei‐Cheng</creatorcontrib><creatorcontrib>Lu, Tzong‐Shi</creatorcontrib><title>Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19</title><title>The Kaohsiung journal of medical sciences</title><addtitle>Kaohsiung J Med Sci</addtitle><description>The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiotensin system (RAS) imbalance and promotion of multi‐organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1‐7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS‐CoV‐2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1‐7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID‐19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID‐19 infection inactivating the ACE2/Ang (1‐7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID‐19 who have comorbidities and may serve as a therapeutic target for COVID‐19 treatment.</description><subject>Angiotensin converting enzyme</subject><subject>Angiotensin II - physiology</subject><subject>Angiotensin Receptor Antagonists - therapeutic use</subject><subject>Angiotensin-Converting Enzyme 2</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Betacoronavirus - pathogenicity</subject><subject>Betacoronavirus - physiology</subject><subject>Blood pressure</subject><subject>Cancer</subject><subject>Cardiovascular disease</subject><subject>Cells</subject><subject>Comorbidity</subject><subject>Conflicts of interest</subject><subject>coronavirus disease 2019</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - physiopathology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Diabetes</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Models, Biological</subject><subject>Mortality</subject><subject>Multiple organ dysfunction syndrome</subject><subject>Obesity</subject><subject>Pandemics</subject><subject>Peptidyl-Dipeptidase A - physiology</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - physiopathology</subject><subject>Proteins</subject><subject>Receptor, Angiotensin, Type 1 - physiology</subject><subject>Renin-Angiotensin System - drug effects</subject><subject>Renin-Angiotensin System - physiology</subject><subject>renin‐angiotensin system</subject><subject>Review</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Signal transduction</subject><subject>Spike Glycoprotein, Coronavirus - physiology</subject><subject>two hits</subject><issn>1607-551X</issn><issn>2410-8650</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ksFuEzEQQFcIRNPChQ9AlrggpATba6-9F6QqUAgU9UBB3Cyvd5w43bVTe9MqNz6Bb-RLcJpSCELIki2N37zRjKYonhA8IRjTlxfLnk4IpaW4V4woI3gsK47vFyNSYTHmnHw9KA5TWmLMqroWD4uDkrKa0pqOik_n1wEt3JDQENCwABTBO__j23ft5y4M4JPzKG3SAD3q9QatunxpdAEbFEMHaPsLVxABTc--zF7nRFI_Kh5Y3SV4fPseFZ9P3pxP341Pz97OpsenY8MlEWPRUsMZpoxrLRpRWiwwEIulNpSYUoiGCy2YrUFgrrnGQEXZmLptGitsbcujYrbztkEv1Sq6XseNCtqpm0CIc6Xj4EwHqq0s4bJs2tJSZhosJeNAsG1zKSsZya5XO9dq3fTQGvBD1N2edP_Hu4WahyslSoyF2Aqe3wpiuFxDGlTvkoGu0x7COinKcF2xqmQyo8_-QpdhHX0eVaYyJzGX_Dc117kB523Idc1Wqo4FJbWsBGOZmvyDyqeF3pngwboc30t4sUswMaQUwd71SLDarpParpO6WacMP_1zKnfor_3JANkB17nM5j8q9eH9R7qT_gQnMNPJ</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Tseng, Yu‐Hsin</creator><creator>Yang, Rei‐Cheng</creator><creator>Lu, Tzong‐Shi</creator><general>Wiley Publishing Asia Pty Ltd</general><general>John Wiley &amp; Sons, Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202006</creationdate><title>Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19</title><author>Tseng, Yu‐Hsin ; Yang, Rei‐Cheng ; Lu, Tzong‐Shi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Angiotensin converting enzyme</topic><topic>Angiotensin II - physiology</topic><topic>Angiotensin Receptor Antagonists - therapeutic use</topic><topic>Angiotensin-Converting Enzyme 2</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Betacoronavirus - pathogenicity</topic><topic>Betacoronavirus - physiology</topic><topic>Blood pressure</topic><topic>Cancer</topic><topic>Cardiovascular disease</topic><topic>Cells</topic><topic>Comorbidity</topic><topic>Conflicts of interest</topic><topic>coronavirus disease 2019</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - physiopathology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Diabetes</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Models, Biological</topic><topic>Mortality</topic><topic>Multiple organ dysfunction syndrome</topic><topic>Obesity</topic><topic>Pandemics</topic><topic>Peptidyl-Dipeptidase A - physiology</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - physiopathology</topic><topic>Proteins</topic><topic>Receptor, Angiotensin, Type 1 - physiology</topic><topic>Renin-Angiotensin System - drug effects</topic><topic>Renin-Angiotensin System - physiology</topic><topic>renin‐angiotensin system</topic><topic>Review</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Signal transduction</topic><topic>Spike Glycoprotein, Coronavirus - physiology</topic><topic>two hits</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tseng, Yu‐Hsin</creatorcontrib><creatorcontrib>Yang, Rei‐Cheng</creatorcontrib><creatorcontrib>Lu, Tzong‐Shi</creatorcontrib><collection>Wiley_OA刊</collection><collection>Wiley-Blackwell Free Backfiles(OpenAccess)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>The Kaohsiung journal of medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tseng, Yu‐Hsin</au><au>Yang, Rei‐Cheng</au><au>Lu, Tzong‐Shi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19</atitle><jtitle>The Kaohsiung journal of medical sciences</jtitle><addtitle>Kaohsiung J Med Sci</addtitle><date>2020-06</date><risdate>2020</risdate><volume>36</volume><issue>6</issue><spage>389</spage><epage>392</epage><pages>389-392</pages><issn>1607-551X</issn><eissn>2410-8650</eissn><abstract>The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiotensin system (RAS) imbalance and promotion of multi‐organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1‐7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS‐CoV‐2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1‐7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID‐19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID‐19 infection inactivating the ACE2/Ang (1‐7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID‐19 who have comorbidities and may serve as a therapeutic target for COVID‐19 treatment.</abstract><cop>BP, Asia</cop><pub>Wiley Publishing Asia Pty Ltd</pub><pmid>32492292</pmid><doi>10.1002/kjm2.12237</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1607-551X
ispartof The Kaohsiung journal of medical sciences, 2020-06, Vol.36 (6), p.389-392
issn 1607-551X
2410-8650
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d6f1583bd3f24cb08845e10fdc21f841
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); Wiley_OA刊; Coronavirus Research Database
subjects Angiotensin converting enzyme
Angiotensin II - physiology
Angiotensin Receptor Antagonists - therapeutic use
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Betacoronavirus - pathogenicity
Betacoronavirus - physiology
Blood pressure
Cancer
Cardiovascular disease
Cells
Comorbidity
Conflicts of interest
coronavirus disease 2019
Coronavirus Infections - drug therapy
Coronavirus Infections - epidemiology
Coronavirus Infections - physiopathology
Coronaviruses
COVID-19
Diabetes
Health aspects
Humans
Hypertension
Infections
Inflammation
Inflammatory diseases
Kinases
Medical prognosis
Models, Biological
Mortality
Multiple organ dysfunction syndrome
Obesity
Pandemics
Peptidyl-Dipeptidase A - physiology
Pneumonia, Viral - drug therapy
Pneumonia, Viral - epidemiology
Pneumonia, Viral - physiopathology
Proteins
Receptor, Angiotensin, Type 1 - physiology
Renin-Angiotensin System - drug effects
Renin-Angiotensin System - physiology
renin‐angiotensin system
Review
SARS-CoV-2
Severe acute respiratory syndrome
Signal transduction
Spike Glycoprotein, Coronavirus - physiology
two hits
title Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A07%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two%20hits%20to%20the%20renin%E2%80%90angiotensin%20system%20may%20play%20a%20key%20role%20in%20severe%20COVID%E2%80%9019&rft.jtitle=The%20Kaohsiung%20journal%20of%20medical%20sciences&rft.au=Tseng,%20Yu%E2%80%90Hsin&rft.date=2020-06&rft.volume=36&rft.issue=6&rft.spage=389&rft.epage=392&rft.pages=389-392&rft.issn=1607-551X&rft.eissn=2410-8650&rft_id=info:doi/10.1002/kjm2.12237&rft_dat=%3Cgale_doaj_%3EA721986744%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2424080585&rft_id=info:pmid/32492292&rft_galeid=A721986744&rfr_iscdi=true